Nawel Bourayou

3.5k total citations · 2 hit papers
25 papers, 2.4k citations indexed

About

Nawel Bourayou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Nawel Bourayou has authored 25 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 2 papers in Obstetrics and Gynecology. Recurrent topics in Nawel Bourayou's work include Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nawel Bourayou is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nawel Bourayou collaborates with scholars based in United States, France and Japan. Nawel Bourayou's co-authors include Martin Frenzel, Masakazu Toi, Susana Barriga, Joohyuk Sohn, Angelo Di Leo, Matthew P. Goetz, Tammy Forrester, In Hae Park, Shin‐Cheh Chen and Olivier Trédan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Nawel Bourayou

23 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nawel Bourayou United States	9	2.1k	1.9k	750	560	203	25	2.4k
Meena Okera Australia	12	1.7k 0.8×	1.5k 0.8×	640 0.9×	492 0.9×	204 1.0×	32	2.0k
Han Koh United States	12	1.9k 0.9×	2.2k 1.2×	866 1.2×	529 0.9×	304 1.5×	27	2.8k
Olga Burdaeva Russia	12	1.7k 0.8×	1.6k 0.9×	640 0.9×	465 0.8×	225 1.1×	27	2.1k
Susana Barriga United States	13	3.3k 1.6×	2.9k 1.5×	1.2k 1.7×	920 1.6×	279 1.4×	26	3.7k
Martin Frenzel United States	14	3.7k 1.7×	3.2k 1.7×	1.3k 1.8×	998 1.8×	402 2.0×	28	4.1k
Fábio Franke United States	19	1.4k 0.7×	1.3k 0.7×	535 0.7×	183 0.3×	558 2.7×	54	2.0k
Manuel Ruíz‐Borrego Spain	19	961 0.5×	1.3k 0.7×	771 1.0×	142 0.3×	447 2.2×	97	1.9k
Katarína Petráková Czechia	23	1.4k 0.7×	2.1k 1.1×	989 1.3×	301 0.5×	645 3.2×	66	2.8k
Luca Moscetti Italy	20	873 0.4×	1.1k 0.6×	361 0.5×	95 0.2×	355 1.7×	98	1.6k
Zhongsheng Tong China	20	754 0.4×	1.2k 0.6×	372 0.5×	170 0.3×	324 1.6×	105	1.7k

Countries citing papers authored by Nawel Bourayou

Since Specialization

Citations

This map shows the geographic impact of Nawel Bourayou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nawel Bourayou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nawel Bourayou more than expected).

Fields of papers citing papers by Nawel Bourayou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nawel Bourayou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nawel Bourayou. The network helps show where Nawel Bourayou may publish in the future.

Co-authorship network of co-authors of Nawel Bourayou

This figure shows the co-authorship network connecting the top 25 collaborators of Nawel Bourayou. A scholar is included among the top collaborators of Nawel Bourayou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nawel Bourayou. Nawel Bourayou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matitashvili, Amiran, Hua Wang, Hsuan‐Cheng Huang, et al.. (2025). 1325MO Retifanlimab (Anti–PD-1 mAb) alone or in combination with Anti-LAG3 ± Anti-TIM3 mAbs In previously untreated, recurrent and/or metastatic (R/M) PD-L1+ HNSCC: A double-blind randomised controlled phase II trial. Annals of Oncology. 36. S772–S772.

Powderly, John D., Martin Gutierrez, Ani Sarkis Balmanoukian, et al.. (2025). First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors. The Oncologist. 30(7).

Gutierrez, Martin, Shou‐Ching Tang, John D. Powderly, et al.. (2025). First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. The Oncologist. 30(7). 2 indexed citations

Gutierrez, Martin, Ani Sarkis Balmanoukian, Anthony F. Shields, et al.. (2023). A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.. Journal of Clinical Oncology. 41(16_suppl). 2541–2541. 1 indexed citations

Piha‐Paul, Sarina A., et al.. (2022). 723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies. Regular and Young Investigator Award Abstracts. A756–A756. 1 indexed citations

Leo, Angelo Di, Masakazu Toi, Tammy Forrester, et al.. (2018). Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. Cancer Research. 78(4_Supplement). P5–21. 2 indexed citations

Goetz, Matthew P., Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology. 35(32). 3638–3646. 1125 indexed citations breakdown →

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →

Leo, Angelo Di, Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Annals of Oncology. 28. v609–v609. 13 indexed citations

10.

Toi, Masakazu, Chiun‐Sheng Huang, Y-H Im, et al.. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy. Annals of Oncology. 28. x28–x28. 3 indexed citations

11.

Iwata, Hiroji, Petros Nikolinakos, J. Thaddeus Beck, et al.. (2017). Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2. Annals of Oncology. 28. v81–v82. 1 indexed citations

12.

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology. 35(15_suppl). 1000–1000. 10 indexed citations

13.

Tolaney, Sara M., Nawel Bourayou, Shom Goel, Anwar Hossain, & Fabrice André. (2017). A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER).. Journal of Clinical Oncology. 35(15_suppl). TPS1109–TPS1109. 2 indexed citations

14.

Tolaney, Sara M., Nawel Bourayou, Shom Goel, Tammy Forrester, & Fabrice André. (2016). monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer. Annals of Oncology. 27. vi99–vi99. 2 indexed citations

15.

Lal, Rohit, Gunnar Hillerdal, Riyaz Shah, et al.. (2015). Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 89(2). 154–160. 21 indexed citations

16.

Goetz, Matthew P., Masakazu Toi, Suzanne Klise, et al.. (2015). MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).. Journal of Clinical Oncology. 33(15_suppl). TPS624–TPS624. 12 indexed citations

17.

Gervais, Radj, G. Robinet, Christelle Clément-Duchêne, et al.. (2013). Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial. Lung Cancer. 80(2). 185–190. 27 indexed citations

18.

Mornex, F., Karine Peignaux, T. Germain, et al.. (2013). Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Lung Cancer. 80(1). 68–74. 6 indexed citations

19.

Lal, Rohit, Nawel Bourayou, Gunnar Hillerdal, et al.. (2013). Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health and Quality of Life Outcomes. 11(1). 163–163. 10 indexed citations

20.

Selle, Frédèric, Joseph Gligorov, Nawel Bourayou, et al.. (2008). [Chemotherapy-induced cardiotoxicity in the elderly].. PubMed. 95 FMC Onco. F89–95. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact